Pharma Sector

The Indian stock market extended its gains on July 2, 2026, with the Nifty closing at 24,175.70 and the Sensex rising 579 points. A strong rebound in IT stocks, lower Brent crude prices, easing US-Iran tensions, a stronger rupee, and lower India VIX boosted investor confidence, while Realty, Auto, Chemicals, Cement, and Consumer Durables also ended in positive territory.

Indian benchmark indices snapped a two-session losing streak on July 1, 2026, as the Nifty 50 climbed above the 24,000 mark and the Sensex gained 444 points. The rally was driven by easing crude oil prices, positive global cues, strong June auto sales, and broad-based buying in Realty, FMCG, Auto, and financial stocks, while IT remained under pressure amid concerns over slowing global technology spending.

Dr. Reddy's Laboratories surged to a new 52-week high as optimism over its biologics pipeline, manageable USFDA observations, new product launches, and strong sector-wide momentum boosted investor confidence. Positive brokerage commentary and expectations of long-term earnings growth further strengthened the stock's rally.

The Indian stock market ended in the red on June 29, 2026, as renewed US-Iran tensions, higher crude oil prices, and profit booking weighed on investor sentiment. Nifty slipped to 23,946 while Sensex lost 372 points. Pharma stocks emerged as the top performers on biosimilar and export optimism, whereas Auto, IT, and Cement sectors witnessed broad-based selling amid cautious global cues.

Bajaj Healthcare share price surged 15% after the company became the first in India to secure the SEC recommendation for Cenobamate tablets. The regulatory milestone is expected to strengthen its CNS portfolio and boost long-term growth prospects.

The Nifty Pharma Index outperformed the broader market by reaching a new 52-week high as pharmaceutical stocks rallied on expanding GLP-1 manufacturing, robust export demand, and positive long-term industry outlook.

Dr. Reddy's Laboratories shares climbed nearly 5% despite the USFDA issuing seven observations at its Bachupally biologics facility. Here's why investors viewed the development positively and what analysts expect next.

Indian benchmark indices ended slightly higher on June 25, 2026, supported by easing Brent crude prices, a stronger rupee, and positive RBI commentary. Auto stocks led gains with strong rallies in Mahindra & Mahindra and Maruti Suzuki, while metal, oil & gas, and IT stocks remained under pressure. Lower market volatility and improving global sentiment helped sustain investor confidence.

The Indian stock market staged a strong recovery on June 24, 2026, with Nifty closing above 24,000 and Sensex surging 790 points. Easing rate hike concerns after RBI Governor Sanjay Malhotra's comments, falling crude oil prices, sustained FII inflows, and optimism surrounding an India-US trade agreement fueled broad-based gains, led by banking, IT, and realty stocks.

Indian Benchmark indices ended sharply lower on June 23, 2026, as a 10% crash in South Korea's Kospi, weakness in IT stocks following Accenture's cautious outlook, and renewed concerns over higher US interest rates triggered broad-based selling. Nifty fell 278.80 points to 23,824.10, while Sensex declined 893.39 points to 76,200.68. Metal and IT stocks led losses, while Pharma emerged as the lone sectoral gainer amid defensive buying.